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Background: Natural killer (NK) cells constitutively express high levels of Tim-3, an immunoregulatory molecule
recently proposed to be a marker for mature and functional NK cells. Whether HIV-1 infection modulates the
expression of Tim-3 on NK cells, or the levels of its ligand Galectin-9 (Gal-9), and how signaling through these
molecules affects the NK cell response to HIV-1 remains inadequately understood.
Results: We analyzed Tim-3 and Gal-9 expression in a cohort of 85 individuals with early and chronic HIV-1
infection, and in 13 HIV-1 seronegative control subjects. HIV-1 infection was associated with reduced expression of
Tim-3 on NK cells, which was normalized by HAART. Plasma concentrations of Gal-9 were higher in HIV-1-infected
individuals than in healthy individuals. Interestingly, Gal-9 expression in immune cells was significantly elevated in
early infection, with monocytes and dendritic cells displaying the highest expression levels, which correlated with
HIV-1 viral loads. In vitro, Gal-9 triggered Tim-3 downregulation on NK cells as well as NK cell activation.
Conclusions: Our data suggest that high expression levels of Gal-9 during early HIV-1 infection can lead to
enhanced NK cell activity, possibly allowing for improved early control of HIV-1. In contrast, persistent Gal-9
production might impair Tim-3 activity and contribute to NK cell dysfunction in chronic HIV-1 infection.
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The human immunodeficiency virus type 1 (HIV-1) af-
fects 34 million adults and children worldwide, and the
ongoing spread of the epidemic resulted in about 2.5
million new infections and 1.7 million deaths in 2011
alone [1]. Novel approaches to prevent the transmission
of HIV-1 are urgently needed, and whether manipulating
innate immune effector cell function could be used as a
strategy to enhance HIV-1 vaccine efficiency remains to
be determined. Recent data suggest that incorporating
components with the potential to harness the antiviral
function of natural killer (NK) cells may represent an at-
tractive option to improve future vaccine designs [2-13].
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reproduction in any medium, provided the orand in shaping the subsequent adaptive immune re-
sponse by interacting with other immune cells, including
dendritic cells (DCs) and CD4+ T cells [14-17]. NK
cell function is regulated by the integration of inhibi-
tory and activating signals generated by an arsenal of
cell surface receptors, with effector functions taking
place when activating signals overcome inhibitory ones
[18]. Importantly, mounting evidence suggests that NK
cells can mediate antiviral activity in HIV-1-infected
humans [2-12]. However, how NK cells recognize and
eliminate HIV‐1‐infected cells and control HIV‐1 repli-
cation and disease progression remains poorly under-
stood to date.
It has recently been described that NK cells constitu-
tively express high levels of T-cell immunoglobulin and
mucin domain-containing molecule 3 (Tim-3) [19-21].
Tim-3 is a type I transmembrane receptor that is also
expressed on specific subsets of CD4+ and CD8+ T cells,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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monocytes (reviewed in [22]), albeit to a lesser extent
than on NK cells [19]. Tim-3 was originally identified as
a marker of terminally differentiated CD4+ Th1 cells
[23], and subsequently associated with T-cell exhaustion
and impaired virus-specific T-cell responses in HIV-1,
hepatitis C virus (HCV) and hepatitis B virus (HBV) in-
fection [24-28]. To date, three ligands have been de-
scribed for Tim-3, including Galectin-9 (Gal-9), a 40-kD
S-type β-galactoside-binding lectin [29], cell-surface
phosphatidylserine [30,31], and—at least in murine
models—the high-mobility group box 1 (HMGB1) pro-
tein [32]. Gal-9 is highly expressed in immune tissues
[33], and while engagement of Tim-3 triggers apoptosis
in CD4+ Th1 cells [29], T cells and thymocytes [34], this
interaction has been suggested to (i) protect activated
CD4+ T cells from HIV-1 infection and replication [35],
(ii) enhance the production of pro-inflammatory cyto-
kines by immature dendritic cells [36,37] and (iii) regu-
late the migration of Th2 cells [38]. Therefore, Tim-3
signaling on immune cells can trigger either inhibitory
or activating signals, with the outcome depending on the
presence of described and potentially as yet undefined li-
gands for Tim-3 [39]. While Tim-3 has been extensively
studied on T cells, much less is known about the impact
of Tim-3-mediated signaling on NK cell responses, not-
ably in the context of viral infections.
Expression of Tim-3 can be induced on NK cells by
various cytokines [20,21], and Tim-3 has recently been
proposed to be a marker for mature and fully functional
NK cells, with those expressing the highest levels of the
receptor displaying the most potent cytotoxic activity or
cytokine production [21]. On NK cells, Tim-3 can act as
an activating co-receptor, as exposure to Gal-9 enhances
IFN-γ production by Tim-3+ NK cells [20], yet it can
also deliver inhibitory signals, given that the ability of
NK cells to kill target cells is lost upon Tim-3 cross-
linking [21]. In accordance with the latter observation,
up-regulation of Tim-3 on NK cells has been associated
with reduced anti-viral properties in chronic hepatitis B
infection, with NK cell cytolytic function being enhanced
upon Tim-3 blockade [40].Table 1 Characteristics of HIV-1-infected study participants an





Early infection 14 51200 1383-1
Chronic untreated 20 8137 5664-2
Chronic treated 17 <50
Elite controllers 17 <50
Viremic controllers 17 382 193-
IQR interquartile range.Progressive HIV-1 infection leads to significant
changes in NK cell phenotype and function, and is asso-
ciated with an expansion of anergic NK cells [41,42].
However, it is not known whether chronic HIV-1 infec-
tion modulates the expression of Tim-3 on NK cells or
the levels of its ligand Gal-9, nor is it understood how
signaling through these molecules affects the NK cell re-
sponse to HIV-1. Here, we describe dysregulated expres-
sion of Tim-3 on NK cells in HIV-1 infection, with
differential responses in early versus chronic HIV-1 in-
fection. Plasma levels of Gal-9 were elevated in HIV-1
-infected individuals and correlated with markers of
HIV-1 disease progression. Moreover, we show that sti-
mulation of Tim-3+ NK cells by Gal-9 leads to NK cell
activation and Tim-3 downregulation in vitro. Our data
suggest that persistent signaling through Tim-3 on NK
cells might result in loss of functionality and accumula-
tion of a Tim-3low NK cell population in vivo, thereby
contributing to the previously described impaired activ-
ity of NK cells in chronic HIV-1 infection.
Results
HIV-1 infection is associated with decreased percentages
of Tim-3+ NK cells
The immunoregulatory molecule Tim-3, previously asso-
ciated with T cell exhaustion and anergy, was recently
shown to mark NK cell maturation and to suppress cell-
mediated toxicity [21]. As progressive HIV-1 infection
leads to the accumulation of dysfunctional NK cells
[41,42], we first examined whether surface expression of
Tim-3 protein on NK cells was altered in individuals at
different stages of HIV-1 infection when compared to
healthy subjects (Table 1). As demonstrated in previous
studies, our data highlight a high degree of variation be-
tween the frequencies of Tim-3-expressing NK cells in
HIV-1 negative individuals (median, 73.36; interquartile
range [IQR], 57.80-80.14) [21] (Figure 1). Similar hetero-
geneity of Tim-3 expression on NK cells was observed
in HIV-1-infected individuals (median, 59.77; IQR,
47.80-66.04), yet percentages of Tim-3+ NK cells were
significantly decreased in HIV-1 infection compared tod healthy controls
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Figure 1 Tim-3 expression is dysregulated in HIV-1 infection. (A) Flow cytometry gating strategy: Gates are set to include CD3- lymphocytes
and exclude dead cells (viability marker+). NK cell subsets are defined by the expression of CD56 and CD16, and Tim-3+ NK cells by using
appropriate fluorescence-minus-one controls. The four right flow cytometry panels show representative examples of Tim-3+ bulk and CD56bright,
CD56dim and CD56neg NK cells in an HIV-1 negative subject (HIV-), an individual with late primary untreated infection, an untreated chronic HIV-1
progressor, and a HAART-treated HIV-1+ patient. Percentages of Tim-3+ bulk NK cells, and MFI of Tim-3 on CD56bright NK cells are indicated on
the top left of the main panel and on the top right of the CD56bright NK cell gate, respectively. (B) Dot plots represent the percentage of Tim-3+
NK cells from 13 healthy individuals and 85 HIV-1-infected subjects (C), including 14 with early untreated HIV-1 infection, 54 with chronic
untreated HIV-1 infection (blue, 17 viremic controllers; green, 17 elite controllers; red, 20 untreated progressors), and 17 with HAART-treated HIV-1
infection. (D) Percentages of Tim-3 + NK cells in CD56bright (CD3-CD56+CD16-), CD56dim (CD3-CD56+CD16+) and CD56neg (CD3-CD56-CD16+) NK
cells in 13 HIV-1 negative and 85 HIV-1-infected subjects. (E) MFI of Tim-3 on CD56bright NK cells in 13 healthy individuals and 14 subjects with
early infection, 54 with chronic untreated HIV-1 infection, including 17 viremic controllers (blue, VC), 17 elite controllers (green, EC), 20 untreated
progressors (red, CU), and 17 with HAART-treated HIV-1 infection (CT). Horizontal lines indicate the median percentages. Statistical differences
with p < 0.05 are indicated and were determined using the Mann–Whitney t test to compare phenotype frequencies between two groups.
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of Tim-3 on NK cells, as measured by the mean fluores-
cence intensity (MFI), trended to be lower in HIV-1infection compared to HIV-1-negative controls, however
the difference did not reach statistical significance (HIV-
1-infected subjects: median, 497; IQR, 387–622; healthy
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stantial decrease in the number of NK cells expressing
Tim-3 was observed as early as in primary HIV-1 infec-
tion, and appeared to be partially restored by highly ac-
tive antiretroviral therapy (HAART) (Figure 1C). The
lowest proportions of Tim-3+ NK cells were found in
viremic controllers (p = 0.002 and p = 0.02 compared to
healthy controls and untreated progressors, respectively),
yet there was an overall high degree of variability in
Tim-3 expression among these subjects (median, 48;
IQR 38.7-64.3), which could not be attributed to differ-
ences in any of the demographic or clinical data ana-
lyzed (data not shown). Interestingly, elite controllers
had similar percentages of Tim-3+ NK cells (median,
58.2; IQR, 47–62.7) as untreated subjects with chronic
viremic HIV-1 infection (median, 62, IQR, 55.1-67).
Functionally distinct NK cell subsets can be defined based
on the level of CD56 and CD16 co-expression on NK cells.
Consequently, we assessed whether Tim-3 expression
differed between CD56brightCD16-, CD56dimCD16+, and
CD56negCD16+ NK cell subsets. The observed decrease in
Tim-3+ NK cells in HIV-1-infected individuals was mainly
driven by a decline in CD56dim and CD56neg NK cells ex-
pressing Tim-3, whereas no change was observed in the
CD56bright compartment (Figure 1D). As observed for
bulk NK cells, decreased percentages of Tim3+ CD56dim
and CD56neg NK cells were found in patients with early
(p = 0.04 and not significant, respectively) and untreated
chronic infection, (i.e. untreated progressors and control-
lers) (p = 0.008 and 0.01, respectively) (Additional file 1).
While proportions of Tim-3+ CD56bright NK cells did not
vary between healthy controls and HIV-1-infected individ-
uals, this subset of NK cells expressed significantly higher
levels of Tim-3 during the early phase of the infection and
in individuals with untreated progressive infection com-
pared to CD56bright NK cells in states of suppressed
viremia, such as in HIV controllers, HAART-treated
HIV-infected individuals and healthy subjects (Figure 1A
and E). Increased expression of Tim-3 on NK cells might
be partly explained by elevated percentages of Tim-3+
CD56bright NK cells in early and progressive infection
(Additional file 1).
CD4+ T-cell counts positively correlated with the pro-
portions of bulk (p = 0.04, Spearman r = 0.28) and
CD56dim (p = 0.03, Spearman r = 0.31) NK cells express-
ing Tim-3 in subjects with untreated chronic progressive
and controlled HIV-1 infection (Additional file 2). In un-
treated subjects with chronic HIV-1 infection and active
HIV replication (i.e. detectable viral loads), percentages
of Tim-3+ bulk (p = 0.006, Spearman r = 0.46) and
CD56dim (p = 0.004, Spearman r = 0.48) NK cells were
even more strongly associated with CD4+ T-cell counts.
No statistically significant associations were observed
with HIV-1 viral loads (data not shown).Taken together, untreated HIV-1 infection was associ-
ated with an early and persisting decrease in percentages
of circulating CD56dim and CD56neg NK cells expressing
Tim-3. Loss of Tim-3+ NK cells over time was more
pronounced in untreated subjects (i.e. untreated chronic
progressors and controllers) with low CD4+ T cell
counts. Tim-3 was transiently upregulated on the im-
munoregulatory CD56bright subset of NK cells during the
early phase of HIV-1 infection, possibly reflecting a
cytokine-induced maturation process as previously dem-
onstrated in vitro [21]. High surface expression of Tim-3
on NK cells persisted on CD56bright NK cells in untreated
individuals with progressive HIV infection, while no differ-
ence was observed in individuals with low or no viremia
present (HAART-treated subjects, controllers and healthy
individuals).
High expression of Galectin-9 in primary HIV-1 infection
To further dissect the potential mechanisms leading to
alterations in Tim-3 expression on NK cells, we exam-
ined whether differential plasma concentration or cellu-
lar expression of Gal-9, a Tim-3 ligand, accounts for the
changes observed in early and chronic HIV-1 infection.
Plasma Gal-9 levels were more than 6-times higher in
late primary HIV-1 infection and twice higher in chron-
ically infected HIV-1-positive subjects than in healthy
controls (Figure 2A). There was no difference in soluble
Gal-9 levels between HAART-treated and untreated sub-
jects with progressive or controlled HIV infection. Like-
wise, the differences between HIV-negative and HIV-1
-positive populations did not reach statistical signifi-
cance. Elevated concentrations of Gal-9 in HIV-1
-infected subjects were positively correlated with viremia
(Figure 2B) and negatively correlated with CD4+ T-cell
counts (Figure 2C).
Gal-9 is produced by a wide range of epithelial and
immune cells [29]. In order to identify the predominant
source of cellular Gal-9, we assessed its intracellular
levels by flow cytometry in different immune cell sub-
sets, including CD4+ and CD8+ T lymphocytes, NK
cells, monocytes, myeloid and plasmacytoid dendritic
cells (mDCs and pDCs, respectively) in a subset of 32
HIV-positive and 9 HIV negative controls (Figure 3A
and B). In healthy individuals, Gal-9 trended to have higher
intracellular expression in monocytes and DCs than in the
other lymphocyte subsets examined (Figure 3C). However,
in individuals with early HIV-1 infection, intracellular
Gal-9 levels were significantly upregulated in all analyzed
peripheral blood mononuclear cells (PBMCs), with mono-
cytes and DCs displaying the highest expression levels. In
contrast, intracellular Gal-9 levels in immune cells from
subjects with chronic HIV-1 infection were similar to
those in healthy individuals (data not shown). In line with
the correlation observed between plasma Gal-9 levels and
Figure 2 High plasma Galectin-9 concentration in early HIV-1
infection. (A) Dot plots represent the logarithmic concentration of
soluble Gal-9 in the plasma of 9 healthy individuals, 11 subjects with
early untreated HIV-1 infection, 15 with HAART-treated HIV-1
infection, and 47 untreated individuals with chronic HIV-1 infection,
including 16 viremic controllers (blue), 15 elite controllers (green),
and 16 subjects with chronic untreated progressive HIV-1 infection
(red), as determined by ELISA. (B) Positive correlation between the
logarithmic viral load and the logarithmic concentration of soluble
Gal-9 in the plasma of 73 HIV-1 individuals, including 11 subjects
with early infection, 16 viremic controllers, 15 elite controllers, 16
subjects with chronic untreated, and 15 with treated HIV-1 infection.
(C) Inverse correlation between the CD4+ T cell counts and the
concentration of soluble Gal-9 in the plasma of 69 HIV-1 individuals,
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CD8+ T cells, NK cells, monocytes, and mDCs all posi-
tively correlated with viral load in subjects with HIV-1 in-
fection (Figure 3D). This association was maintained even
after exclusion of elite controllers from the analysis (data
not shown). Thus, levels of the soluble form of Gal-9 were
overall increased in the plasma of HIV-1-infected individ-
uals, specifically during the early phase of HIV-1 infection,
coinciding with the early upregulation of Gal-9 in all
PBMC subsets analyzed. Cellular expression levels of Gal-

















































































including 7 subjects with early infection, 16 viremic controllers, 15
elite controllers, 16 subjects with chronic untreated, and 15 with
treated HIV-1 infection. CD4-T cell counts were not available for 4
subjects with early HIV-1 infection at the exact date of the
sample draw.Exposure to soluble Gal-9 triggers NK cell degranulation
and Tim-3 downmodulation
Cross-linking of Tim-3 has been shown to inhibit NK
cell cytotoxic functions in vitro [21]. Based on our obser-
vation of increased levels of Gal-9 in natural HIV-1 in-
fection, we sought to next investigate whether Gal-9
could modulate NK cell function in vitro. To address
this question, we compared NK cell function following
treatment with soluble Gal-9 to that upon exposure to
major histocompatibility complex (MHC)-deficient tar-
get cells (i.e. K562 cells). Incubation with Gal-9 triggered
NK cell activation, as measured by CD107a surface
expression, which occurred concomitantly with a de-
creased surface expression of Tim-3 (Figure 4A). Per-
centages of Tim-3+ NK cells were also diminished upon
Gal-9 stimulation, although to a lesser extent (data not
shown). Treatment with soluble Gal-9 did not lead to a
significant increase in production of IFN-γ (unstimu-
lated: median, 0.7; IQR 0.42-0.94; Gal-9; median, 1.014;
IQR, 0.3893- 2.033), as compared to incubation with
K562 cells (median, 9.7; IQR, 5.08- 17.13; p = 0.008 vs.
unstimulated and p = 0.004 vs. Gal-9). In order to further
understand the function executed by Tim-3 in the NK
cell response to Gal-9, we analyzed changes in CD107a
expression on NK cells bearing high (Tim-3bright),
medium (Tim-3dim) or low/no (Tim3low/neg) levels of
Tim-3, and observed that following incubation with Gal-
9, CD107a upregulation on Tim3low/neg NK cells was en-
hanced compared to that of Tim-3bright and Tim3dim NK
cells (Figure 4B). Tim-3bright NK cells were enriched in
CD56bright NK cells which might intrinsically have de-
fective degranulation properties. Therefore, we quanti-
fied CD107a upregulation on Tim-3bright, Tim-3dim and
Tim-3low/neg CD56dim NK cells, and found that upon
Gal-9 stimulation, the activity of CD56dim NK cells ex-









HIV- PHI HIV- PHI HIV- PHI HIV- PHI HIV- PHI HIV- PHI









































































































































Figure 3 Expression of galectin-9 in PBMCs is increased in early HIV-1 infection and correlates with HIV-1 viremia. Flow cytometry
gating strategy to analyze intracellular expression of Gal-9 on (A) CD4+ and CD8+ T cells and (B) pDCs, monocytes or mDCs. Gates are set to
exclude dead cells (viability marker+), and expression of Gal-9 on various lymphocyte subsets is defined by using appropriate fluorescence-minus
-one controls. (C) Dot plots display the MFI of intracellular Gal-9 in the indicated immune cell subsets from 9 healthy (HIV-) and 5 untreated
subjects with early infection as determined by flow cytometry. Horizontal lines indicate the median percentages. Differences where p < 0.05 are
indicated. Histogram overlays display representative examples of intracellular Gal-9 expression in each lymphocyte subset analyzed in healthy
controls (tinted) and in individuals with early HIV-1 infection (transparent) compared to the FMO (dotted line). PHI, early HIV-1 infection (D)
Correlations between the logarithmic viral load and the MFI of intracellular Gal-9 in CD4 + T cells, CD8+ T cells, NK cells, monocytes, mDCS and
pDCs from a subset of 32 HIV-1-positive individuals, including 4 subjects with early infection, 6 viremic controllers, 6 elite controllers, 9 subjects
with chronic untreated, and 7 with chronic treated HIV-1 infection.
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and low (p < 0.0001) levels, showing that CD56bright NK
cells were not introducing a bias in our findings (data
not shown).Overall, these data suggest that exposure to soluble
Gal-9 increases NK cell degranulation and leads to Tim-
3 downregulation. This observation would be consistent

































































































Figure 4 Incubation with soluble Gal-9 increases NK cell function and decreases surface expression of Tim-3. (A) Dot plots represent the
percentages of CD107a + NK cells and the MFI of Tim-3 on NK cells from 8 healthy individuals upon pre-activation with 1 ng/mL of IL-15 and IL-18
overnight followed by stimulation with either 0.9 μg/mL of soluble Gal-9 for another 16 h or K562 target cells at an effector:target ratio of 10:1 for 6 h.
Representative primary flow cytometry panels show CD107a upregulation (upper panel) and Tim-3 expression (lower panel) on NK cells that were left
unstimulated, or were activated as indicated. (B) Unstimulated or Gal-9-activated NK cells were divided into Tim-3bright, Tim-3dim and Tim-3low/neg so
that the bright and the low/neg subpopulations each consistently represents about 25% of the bulk NK cells, and subsequently analyzed for CD107a
expression. Representative primary flow panel shows an example of subdivision of NK cells according to Tim-3 expression. Percentages of positive NK
cells and median fluorescence intensity are indicated. Histograms display CD107a upregulation in each subset following incubation with soluble Gal-9.
Horizontal lines indicate the median percentages. Statistically significant difference reached when p < 0.05 is indicated.
Jost et al. Retrovirology 2013, 10:74 Page 7 of 12
http://www.retrovirology.com/content/10/1/74downmodulation on NK cells, leading to a contraction
of the Tim-3-expressing NK cell population in chronic-
ally infected HIV-1+ individuals.
Discussion
An emerging body of data indicates that the Tim-3/Gal-
9 pathway may play a critical role in the regulation of
both adaptive and innate immune mechanisms
[20,21,23-29,34-38,40]. In this study, we investigated
changes in the expression of the immuno-regulatory re-
ceptor Tim-3 on NK cells, and that of its ligand Gal-9 in
HIV-1 infection. To our knowledge, this is the first re-
port demonstrating loss of peripheral Tim-3+ NK cells
in subjects with early and chronic untreated HIV-1 in-
fection, with lower CD4+ T cell counts in chronically
infected subjects expressing decreased percentages of
Tim-3+ NK cells (Figure 1 and Additional file 1). While
the observed decrease in Tim-3-expressing NK cells did
not affect the CD56bright NK cell subset, this specific
subpopulation displayed an increased surface expressionof the receptor during late primary HIV-1 infection,
which occurred concomitantly with increased expression
of Gal-9, predominantly by monocytes and mDCs (Figures 2
and 3). Together with previous reports, our data strongly
suggest that enhanced exposure to Gal-9 during early
HIV-1 infection can lead to NK cell activation, which
might be beneficial to early control of HIV-1 replication
(Figure 4) [20,35]. Involvement of Tim-3 in early control
of HIV-1 infection and subsequent chronic exposure to
Gal-9 may eventually lead to a loss of Tim-3 expression
on NK cells, resulting in diminished responsiveness to its
ligands.
It has been demonstrated that treatment with IL-12
and IL-18 leads to Tim-3 upregulation on CD56bright NK
cells, and increases the ability of this subset to produce
IFN-γ in response to Gal-9 [20,21]. In line with these re-
sults, we show here that Tim-3 surface density is
upregulated on peripheral CD56bright NK cells during
early HIV-1 infection and in untreated chronic HIV-1
infection, representing populations with high viremia. In
contrast to recently published studies, we did not detect
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cells with Gal-9 in vitro. However, our experiments were
performed in the presence of IL-15 and IL-18 but with-
out addition of IL-12, and the absence of this key cyto-
kine might account for this discrepancy. Elevated
inflammatory cytokine concentrations, including that of
IL-12 and IL-18, have been previously described in indi-
viduals with early HIV-1 infection [43,44]. Likewise, on-
going viral replication in subjects with progressive HIV-
1 infection most likely sustains a chronic inflammatory
status. In these specific contexts, elevated concentrations
of IL-12 and IL-18 might promote upregulation of Tim-
3 on CD56bright NK cells in vivo as observed in our co-
horts of subjects with early or progressive untreated
HIV-1 infection. Moreover, we observed that early HIV-
1 infection is characterized by increased plasmatic levels
of Gal-9. Altogether, these conditions may result in a
Gal-9-induced enhancement of in vivo IFN-γ production
by NK cells during the primary phase of the infection.
Accordingly, in early HIV-1 infection, CD4+ T-cell
counts negatively correlated with surface density of
Tim-3 on CD56bright NK cells as measured by the MFI
(Additional file 3). This association between low CD4+
T-cell counts and high Tim-3 expression on CD56bright
NK cells may partly reflect enhanced IFN-γ-mediated
elimination of HIV-1-infected CD4+ T cells. A recent
study by Finney et al. also found increased expression of
Tim-3 in CD56high NK cells from untreated chronic sub-
jects, yet the authors did not observe a significant de-
crease in percentages of Tim-3+ CD56low NK cells [45].
However, low numbers of HIV-1-infected subjects in-
cluded in this study, use of alternate Tim-3 reagents and
particularly, differences in the NK cell classification ap-
proach for CD56high and CD56low NK cells may account
for these distinct observations. Thus, our data suggest
that increased surface density of Tim-3 on NK cells dur-
ing early HIV-1 infection, followed by a loss of periph-
eral blood Tim-3+ subsets of cytotoxic NK cells, may be
linked to progressive HIV-1 infection.
Over time, it is likely that constant exposure of Tim-3+
NK cells to Gal-9, which is more abundant in the plasma
of individuals with chronic HIV-1 infection than in
healthy subjects, contributes to Tim-3 downregulation. In-
deed, it has been suggested that both direct and indirect
stimulation can trigger internalization of activating NK
cell receptors to prevent activation-induced cell death
[46,47]. While it is clear that in the presence of specific cy-
tokines, the interaction between Tim-3 and Gal-9 results
in enhanced IFN-γ production by CD56bright NK cells, it
remains to be elucidated whether engagement of Tim-3
triggers NK cell activation and how NK cell function is
modulated by changes in Tim-3 expression in the context
of viral infections. Gleason and colleagues reported dimin-
ished expression of Tim-3 on NK cells from patientsundergoing allogeneic hematopoietic stem cell transplan-
tation for the treatment of leukemia, and lower expression
correlated with impaired IFN-γ production, further
supporting a role for Tim-3 signaling in enhancing cyto-
kine production by NK cells [20]. In accordance with this
concept, we show that engagement of Tim-3 with soluble
Gal-9 triggers NK cell activation and Tim-3 down-
modulation. Following exposure to Gal-9, NK cells with
the most important CD107a upregulation were those with
no or very low Tim-3 surface expression as a consequence
of stimulation (Figure 4). These data do not directly ex-
clude the possibility that soluble Gal-9 used to stimulate
NK cells competes with the monoclonal antibody for
binding to Tim-3, yet the fact that K562-activated NK
cells also presented a significant decrease in surface ex-
pression of Tim-3 suggests that NK cell activation gener-
ally triggers Tim-3 downmodulation. Finally, we assessed
whether NK cell activation by Gal-9 is mediated by Tim-3
by adding antibodies directed against this receptor, yet
Tim-3 blockade did not significantly alter CD107a ex-
pression on NK cells, suggesting that engagement of
alternate receptors by Gal-9 might contribute to this
effect (Additional file 4). Accordingly, a controversially
discussed publication by Leitner et al. recently suggested
that Tim-3 does not act as a receptor for Gal-9 [48]. How-
ever, this study focused on Tim-3/Gal-9 interaction in T
cells, and therefore caution has to be taken while extrapo-
lating these results to NK cells. In particular, Tim-3 en-
gagement may have distinct outcomes depending on the
immune cell type expressing this receptor, suggesting that
the nature of the signal mediated by Tim-3 might depend
on the presence of downstream signaling molecules,
which differ from one immune cell type to another. More-
over, in the manuscript by Leitner et al., stimulation of
Tim-3 by Gal-9 was performed using membrane-bound
and not soluble Gal-9, and this difference in methodology
might impact the signal and partly explain the discrepan-
cies between the results obtained in this setting compared
to previous publications.
While further investigations are warranted to fully
understand the effect of Tim-3 on NK cell function in
HIV-1 infection, the permanent low expression of this
potential co-activating receptor on NK cells may con-
tribute to the previously described loss of NK cell func-
tion associated with chronic HIV-1 infection [41,42]. In
line with this hypothesis, we show that CD56neg NK
cells, which constitute an anergic subset of NK cells that
accumulates in HIV-1 infection [41,42], displayed the
lowest levels of Tim-3 expression. An alternative explan-
ation of the observed decreased percentages of periph-
eral blood Tim3+ CD56dim NK cells in HIV-1-infected
individuals could be tissue redistribution and recruitment
of these highly functional cells into lymphoid tissue com-
partments, such as lymph nodes or mucosal sites.
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ipheral blood and hepatic NK cells from subjects with
chronic HBV infection had increased expression of Tim-
3, and blockade of this receptor with an antibody di-
rected at Tim-3 increased NK cell functions, suggesting
that Tim-3, alone or in combination with other recep-
tors, can contribute to delivering inhibitory signals [40].
It is conceivable that the NK cell surface concentration
of Tim-3 determines whether the signal will be acti-
vating or inhibitory, as has been proposed for the im-
munoregulatory receptor 2B4 [49]. In contrast, other
published data reveal that cross-linking with an anti-Tim
-3 antibody abrogates cytolytic functions triggered via
potent activating NK cell receptors [21]. Overall, the
mechanisms underlying Tim-3 signaling appear to be
highly complex and remain incompletely understood. It
will therefore be critical to assess how natural ligands
for Tim-3 modulate NK cell functions.
It was previously shown that individuals with chronic
HIV-1 infection and high viral loads (>10,000 copies/mL)
have higher levels of Gal-9 in the plasma compared to
those with low viremia [35]. In our study we found that
low CD4+ T cell counts and high HIV-1 viral loads were
both associated with high concentrations of Gal-9 in the
plasma from HIV-1-infected patients (Figure 3). Meas-
urement of intracellular Gal-9 showed that among all
lymphocyte subsets analyzed, the ligand for Tim-3 is
mainly produced by monocytes and mDCs, and signifi-
cantly upregulated in these cell types during early HIV-
1 infection. As it has been demonstrated that Gal-9 can
be both secreted and expressed at the surface of antigen
presenting cells [24], it will be of paramount importance
to evaluate the role of Tim-3/Gal-9 interactions in the
cross-talks between NK cells and DCs, and how these
impact the HIV-1-specific adaptive immune responses.
It is tempting to speculate that engagement of Tim-3 in
the mucosa very early in HIV-1 infection may lead to
potent NK cell activation, and could limit viral spread.
Conclusions
To conclude, while recent data indicate the existence of
potential Tim-3-independent interactions between Gal-9
and NK cells [50], our study suggests that interactions
between Gal-9 and Tim-3 can play a role in regulating
NK cell function in HIV-1 infection. Further experi-
ments will be required to determine how Tim-3 signal-
ing pathways in NK cells differ from those identified in
T cells and DCs so far, and how it affects NK cell func-
tion in both early and chronic infection. Overall, these
data contribute to a better understanding of the innate
immune mechanisms displayed in HIV-1 infection, pro-
viding a basis for further analysis into the contribution
of NK cell receptors in the control of HIV-1 infection.Notably, molecules that can increase Gal-9 concentra-
tion at mucosal sites might enhance early control of
HIV-1 replication, as previously suggested [35], and offer
a strategy worth exploring for incorporation in future
immunotherapeutic interventions or strategic HIV-1
vaccine design.Methods
Study subjects (n = 98)
The study included 14 individuals identified during un-
treated early HIV-1 infection (Fiebig stage IV–V), 54
subjects with untreated chronic HIV-1 infection, which
included 20 individuals with untreated progressive dis-
ease (median viral load, 8137; IQR, 5664–21175), 17 elite
controllers with HIV-1 RNA below the limit of detection
of standard viral load assays (<50 copies/mL) for at least
1 year ( among the 17 elite controller subjects studied
here, viral loads were suppressed for a median of 3.5
(IQR 1.13-7.5) years), 17 viremic controllers with un-
treated asymptomatic HIV-1 infection (HIV-1 RNA
<2000 copies/mL), 17 HIV-1–positive individuals
HAART-treated with viral loads <50 copies/mL for >1 year
(median, 9.1; range, 1.9-15.5), and 13 healthy HIV-1 unin-
fected controls (Table 1). The study was approved by the
Massachusetts General Hospital Institutional Review
Board, and written informed consent was obtained from
all study participants.Flow cytometric analysis
To quantify Tim-3 expression on NK cells, cryopreserved
PBMCs were thawed and stained with anti-CD3-Qdot605
(Invitrogen), anti-CD56-A700, anti-CD16-APC-Cy7 (BD
Biosciences) and anti-Tim-3-PE (BioLegend, clone F38-
2E2). Gating strategy is outlined in Figure 1A. Intracellular
staining of Gal-9 was performed using the Fix & Perm®
Medium A and B kit (Invitrogen) and anti-gal-9-PE
(BioLegend, clone 9 M1-3) following surface staining with
anti-CD3-Qdot605, anti-CD4-Qdot655 (Invitrogen), anti-
CD56-PECy7, anti-CD16-APC-Cy7, anti-CD11c-APC,
anti-CD8a-A700, anti-CD123-PECy5, anti-CD14-Pacific
Blue (BD Biosciences). The LIVE/DEAD® Fixable Blue
Dead Cell Stain Kit was used prior to any surface staining
to exclude dead cells (Invitrogen). NK cell populations
were defined as lymphocytes that were CD3-negative and
included CD56bright (CD3-CD56+CD16-), CD56dim (CD3-
CD56+CD16+), and CD56neg (CD3-CD56-CD16+) NK cell
subsets. The mDC population was defined as CD3-CD14-
CD56-CD11c+CD123-, the pDC population as CD3-CD14-
CD56-CD11c-CD123+, and the monocyte population as
CD3-CD14+CD56-CD11c+CD123- (Figure 4B). Data were
acquired on LSRII 4 laser system using FacsDiva™ software
version 8.8.3 (BD Biosciences). The frequency and pheno-
types of NK cells, CD4+ and CD8+ T cells, monocytes,
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version 7.6.5 (Treestar, Ashland, OR).
Quantification of Gal-9 in plasma
Plasma specimen collected at the same time points as
PBMC samples were available for a subset of 82 study
participants (15 elite and 16 viremic controllers, 16 indi-
viduals with chronic untreated HIV-1 infection, 15 HIV-
1-positive treated individuals, 11 individuals identified
during late primary HIV-1 infection, and 9 healthy HIV-
1 uninfected controls). The plasma concentration of
Gal-9 was quantified using an ELISA kit for soluble hu-
man Gal-9 (Uscn Life Science Inc.), according to the
manufacturer’s protocol. This kit allows for the detection
of Gal-9 with a dynamic range of 7.8 to 500 pg/mL.
Flow cytometric analysis of NK cell function
NK cell activation was quantified after overnight pre-
stimulation of fresh PBMCs with 1 ng/mL of IL-15 and
IL-18, followed by incubation with either MHC–devoid
K562 cells at an effector-to-target cell ratio of 10:1 for
6 h as previously described [51] or with 0.9 μg/mL of
soluble Gal-9 (R&D) for 16 h in 1 mL of RPMI-1640
supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 μg/ml streptomycin and 100 U/ml
penicillin, 10 μl/ml anti-CD107a-PE-Cy5 antibody (BD
Biosciences), 5 μg/ml brefeldin A (Sigma) and 0.3 μg/ml
monensin (Golgi stop; BD Biosciences). Medium alone
served as the negative control, and PMA/ionomycin (2.5
and 0.5 μg/mL, respectively) served as the positive con-
trol. PBMCs were then stained with anti-CD3-Pacific
Blue, anti-CD56-PE-Cy7, anti-CD16-APC-Cy7 (BD Bio-
sciences) and anti-Tim-3-PE (Biolegend) antibodies,
fixed, permeabilized (as described above) and finally
stained for intracellular IFN-γ using anti-IFN-γ-FITC
antibody (BD Biosciences). Multiparameter flow cyto-
metric analysis was performed on LSRII 4 laser instru-
ment (BD Biosciences). The frequency and phenotypes
of NK cells were defined using FlowJo™ version 7.6.5
(Treestar).
Statistical analyses
The non-parametric Kruskal–Wallis test was used to
compare phenotype frequencies and functional differ-
ences among patient groups when more than two groups
were involved, and was followed by a Dunns Multiple
Comparison post-test. The Mann–Whitney t test was
used to compare phenotype frequencies and functional
differences between two groups. The p-values were two-
sided. Spearman’s rank correlation was used for correl-
ation analysis. p-values of <0.05 were considered signifi-
cant. Statistical analyses were performed using the
GraphPad Prism™ software version 5.04.Additional files
Additional file 1: Percentages of Tim-3+ CD56bright (CD3-
CD56+CD16-), Tim-3+ CD56dim (CD3-CD56+CD16+) and Tim-3+
CD56neg (CD3-CD56-CD16+) NK cells in 13 HIV-1 negative (HIV-)
and 14 subjects with early untreated HIV-1 infection (Early), 20
untreated progressors (red, CU), 17 viremic controllers (blue, VC),
17 elite controllers (green, EC), and 17 with HAART-treated HIV-1
infection (CT). Horizontal lines indicate the median percentages.
Statistically significant difference reached when p < 0.05 is indicated.
Additional file 2: Positive correlation between the percentages of
Tim-3+ CD56dim NK cells and CD4+ T cell counts from subjects with
untreated chronic HIV-1 infection and available clinical data
(matching the day of PBMCs and plasma sample collection), including
17 elite controllers (green), 17 viremic controllers (blue) and 17
individuals with untreated chronic progressive infection (red).
Additional file 3: Inverse correlation between the MFI of Tim-3 on
CD56bright NK cells and CD4+ T cell counts in 9 subjects with early
HIV-1 infection and available clinical data matching the date of the
PBMCs sample used for the quantification of Tim-3 on NK cells.
Additional file 4: Downregulation of Tim-3 (upper graph) and
upregulation of CD107a (lower graph) on NK cells stimulated with
Gal-9 in the presence of Tim-3 blocking antibodies. PBMCs from 3
healthy individuals were incubated overnight in the presence of 1 ng/mL
of IL-12 and 10 ng/mL of IL-18 prior to incubation with Gal-9 (1 ug/mL) or
K562 cells (effector:target ratio of 10:1) in the presence or absence of anti-
Tim-3 antibodies (20 ug/mL) for 6 h as indicated. Lactose (20 mM final) was
used as a control for Gal-9 blockade.
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